Literature DB >> 10832109

Prognostic indicators in differentiated thyroid carcinoma.

D S Dean1, I D Hay.   

Abstract

BACKGROUND: Thyroid cancer ranges from well-differentiated lesions with an excellent prognosis to anaplastic carcinoma, which is almost uniformly fatal. Thus, methods to assess the behavior of thyroid malignancies are necessary to arrive at appropriate treatment decisions.
METHODS: We discuss the factors that affect the prognosis of patients with well-differentiated thyroid malignancies, including papillary, follicular, Hürthle cell, and medullary thyroid carcinomas. We also review the presentation, therapy, and outcome of patients seen at our center over a span of 50 years. These data have identified those prognostic factors that are predictive of survival and recurrence in differentiated thyroid cancer.
RESULTS: Several classifications with different variables have been developed to define risk-group categories. Three widely used systems, in addition to the TNM staging system, include AGES, AMES, and MACIS.
CONCLUSIONS: A better understanding of independently important prognostic variables will result in improved patient care and treatment.

Entities:  

Mesh:

Year:  2000        PMID: 10832109     DOI: 10.1177/107327480000700302

Source DB:  PubMed          Journal:  Cancer Control        ISSN: 1073-2748            Impact factor:   3.302


  41 in total

1.  Thyroid cancer presentation and treatment in the United States.

Authors:  Lindsey Enewold; Linda C Harlan; Jennifer L Stevens; Elad Sharon
Journal:  Ann Surg Oncol       Date:  2014-11-01       Impact factor: 5.344

2.  Post-surgical ablation of thyroid residues with radioiodine in Ukrainian children and adolescents affected by post-Chernobyl differentiated thyroid cancer.

Authors:  V Oliynyk; O Epshtein; T Sovenko; M Tronko; R Elisei; F Pacini; A Pinchera
Journal:  J Endocrinol Invest       Date:  2001-06       Impact factor: 4.256

3.  Risk Stratification in Differentiated Thyroid Cancer: From Detection to Final Follow-up.

Authors:  R Michael Tuttle; Ali S Alzahrani
Journal:  J Clin Endocrinol Metab       Date:  2019-03-15       Impact factor: 5.958

Review 4.  Approach to and treatment of thyroid disorders in the elderly.

Authors:  Maria Papaleontiou; Megan R Haymart
Journal:  Med Clin North Am       Date:  2012-02-14       Impact factor: 5.456

Review 5.  New insights in risk stratification of differentiated thyroid cancer.

Authors:  Maria Papaleontiou; Megan R Haymart
Journal:  Curr Opin Oncol       Date:  2014-01       Impact factor: 3.645

6.  Mortality-related factors in 1056 radioiodine-treated patients with well-differentiated thyroid cancer in southern Thailand.

Authors:  Tada Yipintsoi; Teerapon Premprabha; Alan Geater; Tanyaluck Thientunyakij; Suchitra Thongmak
Journal:  World J Surg       Date:  2010-02       Impact factor: 3.352

7.  Clinical implication of cancer adhesion in papillary thyroid carcinoma: clinicopathologic characteristics and prognosis analyzed with degree of extrathyroidal extension.

Authors:  Seung Pil Jung; Minkuk Kim; Jun-Ho Choe; Jee Soo Kim; Seok Jin Nam; Jung-Han Kim
Journal:  World J Surg       Date:  2013-07       Impact factor: 3.352

8.  Brain metastases from papillary thyroid carcinomas.

Authors:  Farnaz C Tahmasebi; Peter Farmer; Suzanne Z Powell; Kenneth D Aldape; Gregory N Fuller; Shital Patel; Peter Hollis; David Chalif; Mark B Eisenberg; Jian Yi Li
Journal:  Virchows Arch       Date:  2013-03-27       Impact factor: 4.064

9.  Should patients with remnants from thyroid microcarcinoma really not be treated with iodine-131 ablation?

Authors:  Rosj Gallicchio; Sabrina Giacomobono; Daniela Capacchione; Anna Nardelli; Francesco Barbato; Antonio Nappi; Teresa Pellegrino; Giovanni Storto
Journal:  Endocrine       Date:  2013-03-28       Impact factor: 3.633

10.  Clinical significance of CD146 and latexin during different stages of thyroid cancer.

Authors:  Zakaria Y Abd Elmageed; Krzysztof Moroz; Emad Kandil
Journal:  Mol Cell Biochem       Date:  2013-05-28       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.